Tevas Ophthalmology Biosimilar Ongavia To Treat Age-Related Macular Degeneration Receives Uk Mhra Approval

Tevas Ophthalmology Biosimilar Ongavia To Treat Age-Related Macular Degeneration Receives Uk Mhra Approval

By, Admin 20 May 2022

Teva Pharmaceutical Industries Ltd Welcomes The Uk Medicines & Healthcare Regulatory Agency (Mhra) Decision To Grant A Licence For Ongavia, A Biosimilar To Lucentis (Ranibizumab), An Eye Injection. The United Kingdom Is The First Country In Europe To Authorize Commercialization Of Ongavia For The Treatment Of Neovascular (Wet) Age-Related Macular Degeneration (Amd).Ongavia Is Also Licenced For: The Treatment Of Visual Impairment Due To Diabetic Macular Oedema (Dme); The Treatment Of Proliferative Diabetic Retinopathy (Pdr); The Treatment Of Visual Impairment Due To Macular Oedema Secondary To Retinal Vein Occlusion (Branch Rvo Or Central Rvo); And The Treatment Of Visual Impairment Due To Choroidal Neovascularisation (Cnv).Ranibizumab Inhibits Vascular Endothelial Growth Factor (Vegf), Which Is Responsible For The Excessive Formation Of Blood Vessels In The Retina. Teva'S Biosimilar Ranibizumab Is Highly Similar To Its Reference Medicine In Terms Of Clinical Efficacy, Ocular And Systemic Safety In The Treatment Of Patients With Amd And Its Other Indications, As Shown In The Columbus-Amd Study (A Randomized, Double-Masked, Parallel Group, Multi-Centre Phase Iii Study).Welcoming The News, Richard Daniell, Executive Vice President, Teva Europe Commercial, Said:

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!